Muscle-bone interactions in dystrophin-deficient and myostatin-deficient mice.
We have investigated muscle-bone interactions using two mouse mutants that are known to differ from normal mice in skeletal muscle growth and development: mice lacking myostatin (GDF8) and mice lacking dystrophin (mdx). Myostatin-deficient mice show increased muscle size and strength compared to normal mice, whereas the mdx mouse is a well-established animal model for Duchenne muscular dystrophy. The mdx mice have significantly larger hindlimb muscles than controls, and histological sections of the quadriceps muscles show dystrophic changes with extensive fibrosis. Femoral bone mineral density (BMD) and fracture strength (Fu) are significantly greater in mdx mice than controls, and these variables are more strongly correlated with quadriceps muscle mass than with body mass. In contrast, mdx mice do not shower high bone mineral density in the spine relative to controls, whereas myostatin-deficient mice have significantly increased BMD in the lumbar spine compared to normal mice. Both mdx mice and myostatin-deficient mice have expanded femoral trochanters for attachment of large hindlimb muscles, and both mutant strains show increased cross-sectional area moments of inertia mediolaterally (Iyy) but not anteroposteriorly (Ixx) compared to normal mice. These data suggest that lean (muscle) mass is a significant determinant of bone mineral density and strength in the limb skeleton, even when accompanied by a dystrophic phenotype. Likewise, increased muscle mass produces a marked increase in the external dimensions of muscle attachment sites, even when increased muscle size is accompanied by extensive fibrosis and muscle weakness.
Montgomery
Eric
E
Department of Cellular Biology and Anatomy, Medical College of Georgia, Augusta, Georgia 30912, USA.
Pennington
Catherine
C
Isales
Carlos M
CM
Hamrick
Mark W
MW
D000818:Animals; D015519:Bone Density; D004195:Disease Models, Animal; D016189:Dystrophin / Q000172:deficiency* / Q000502:physiology; D005260:Female; D005269:Femur / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D008159:Lumbar Vertebrae / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018101:Mice, Inbred mdx; D008817:Mice, Mutant Strains; D018485:Muscle Fibers, Skeletal / Q000473:pathology / Q000502:physiology; D018908:Muscle Weakness / Q000378:metabolism / Q000503:physiopathology; D018482:Muscle, Skeletal / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology*; D009137:Muscular Dystrophy, Animal / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D020388:Muscular Dystrophy, Duchenne / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D055435:Myostatin; D016212:Transforming Growth Factor beta / Q000172:deficiency* / Q000502:physiology
D016189:Dystrophin; C525912:Mstn protein, mouse; D055435:Myostatin; D016212:Transforming Growth Factor beta